BCIQ Profiles

Company Profile Report

New shot at sepsis

How Critical Pressure’s CPL001 could stabilize septic shock patients

Critical Pressure Ltd. is developing a therapy for septic shock to combat hypotension more effectively than marketed vasopressors, and without their side effects.

Sepsis is a systemic inflammatory response triggered by severe bacterial infection. Over 30% of patients with sepsis develop septic shock, which is characterized by severe hypotension that can lead to tissue damage, multiple organ failure and death.

Vasopressors, particularly those based on endogenous vasoconstrictors like norepinephrine, are used

Read the full 709 word article

How to gain access

Continue reading with a
two-week free trial.